Obigen Pharma Inc. (TPEX:7876)

Market Cap	4.11B
Revenue	n/a
Net Income	n/a
Shares Out	106.92M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	120,109
Average Volume	136,339
Open	39.10
Previous Close	38.45
Day's Range	37.25 - 39.10
52-Week Range	34.55 - 69.00
Beta	n/a
RSI	49.88
Earnings Date	n/a

About Obigen Pharma

Obigen Pharma Inc. researches, develops, produces, manufactures, and sells botulinum toxin products in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei City, Taiwan.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7876